Skip to content

Released May 16, 2022, before the open

10-Q filed May 16, 2022, 46 days after period end · 0001558370-22-008847

Q1 2022 · 10-Q
Revenue$16.09M+42.1% vs Q1 2021+88.2% vs Q4 2021
Net Income-$2.29MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.05N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$1,870,000N/M
Operating Cash Flow-$5,829,000N/M
Free Cash Flowderived-$6,058,000N/M
Margins · derived
Operating margin-11.6%+21.1 pt vs Q1 2021
Net margin-14.2%+34.2 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Revenue$16.09M$11.32M$21.65M$10.44M
Net Income-$2.29M-$5.48M$1.67M-$7.26M
EPS Diluted-$0.05-$0.14$0.10-$0.50

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR